Abstract

The tumorigenesis of gastrointestinal and pancreatic tumors (GEPNETs) is poorly understood. We need a better understanding of the molecular alterations in GEPNETs to obtain an accurate classification, and it may also provide targets for therapeutic intervention. Purpose of Paper. The purpose of this paper was to critically examine recent advances in the molecular understanding of GEPNETs gained from genome-wide and transcriptome-wide profiling studies. Special emphasis was put on diagnostic, predictive, and therapeutic implications of profiling studies. Results. Pancreatic neuroendocrine tumours (PNETs) were characterised by a distinct pattern of chromosomal alterations and a higher degree of chromosomal instability (CIN) than ileal carcinoids. Subgroups of PNETs and ileal carcinoids were identified on the basis of specific chromosomal alterations. Exome sequencing identified mutations in MEN1, ATRX/DAXX, and mTOR pathway genes as being frequent events in sporadic PNETs. Expression profiles of PNETs and ileal carcinoids were found to be different, and allowed identification of subgroups of tumors, as well discrimination between benign and malignant tumors. The molecular data provided a number of candidate genes and pathways suitable for targeted therapy. For PNETs, candidate targets include BRAF, KRAS, TERT, EGFR, RET, MDM2, IGF, MET/HGF, ANG2, LCK, PDGFRB, AKT-mTOR, and SSTR2. Some of these targets have already been evaluated in clinical trials (mTOR and SSTR2). For ileal carcinoids, significantly fewer candidate targets were provided, including ERBB2 (HER2), RET, APLP1, and Notch. Conclusion. Profiling of GEPNETs is a powerful tool for discovery of novel targets for therapeutic intervention. Further studies, combining genome, epigenome, transcriptome, and proteome data are needed to enable us to identify clinically relevant targets in GEPNETs.

Highlights

  • Gastrointestinal and pancreatic neuroendocrine tumors (GEPNETs) are rare, and they account for 1-2% of all gastrointestinal malignancies

  • All GEPNETs are regarded as being potentially malignant and they are graded on the basis of mitotic count and Ki67 index into two categories: neuroendocrine tumor (NET) of grades 1-2 and neuroendocrine carcinoma (NEC) of grade 3

  • A number of high-throughput techniques are available for the analysis of molecular alterations in cancers including array-based comparative genomic hybridisation, single nucleotide polymorphism (SNP) arrays [5, 6], nextgeneration sequencing [4], expression arrays [5, 7], and protein profiling [8]

Read more

Summary

Introduction

Gastrointestinal and pancreatic neuroendocrine tumors (GEPNETs) are rare, and they account for 1-2% of all gastrointestinal malignancies. A number of high-throughput techniques are available for the analysis of molecular alterations in cancers including array-based comparative genomic hybridisation (aCGH), single nucleotide polymorphism (SNP) arrays [5, 6], nextgeneration sequencing [4], expression arrays [5, 7], and protein profiling [8]. These technologies have only recently been applied to GEPNETs. A search on PubMed performed in September 2011 revealed 24 publications describing studies. A summary of the studies on GEPNETs, togethe with a critical evaluation is given below

Genomic Profiling of PNETs
Expression Profiling of PNETs
Genomic Profiling of Ileal Carcinoids
Expression Profiling of Ileal Carcinoids
Summary
Findings
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.